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Abstract 
Erythema multiforme is an uncommon acute inflammatory disorder caused by exposure to microbes or drugs. 
Erythema multiforme minor typically affects only one mucosa and can be associated with symmetrical target skin 
lesions on the extremities. The disease usually occurs in patients in their 3rd and 4th decade of life, but can also 
affect children and adolescents. Alendronate sodium has been approved for the prevention and treatment of osteo-
porosis in postmenopausal women, but is associated with adverse events. This study reports and discusses a case of 
erythema multiforme minor. In addition, a literature search of articles published in PubMed-Medline was perfor-
med. The case was a 96-year-old woman who had taken alendronate. Intraoral clinical examination demonstrated 
hypersalivation and macrocheilia of the lower lip, associated with an ill-defined ulcer with erythematous borders 
measuring 20 mm in greatest diameter and covered with serofibrinous exudates. The aging of the population in 
developed and developing countries has increased the use of alendronate sodium to prevent osteoporosis and clini-
cians should be aware of possible oral adverse events associated with this drug.
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Introduction
Erythema multiforme (EM) is an uncommon acute 
inflammatory disorder that affects the skin, mucous 
membranes, or both. The disease has been classified into 
different variants, including the minor and major forms, 
which can affect the mouth alone or be associated with 
skin eruption in the presence or absence of oral or other 
mucosal lesions (1). Erythema multiforme minor ty-
pically affects only one mucosa and can be associated 
with symmetrical target skin lesions on the extremities. 
The disease usually occurs in patients in their 3rd and 4th 
decade of life, but can also affect children and adoles-
cents (1,2). In contrast, EM major typically affects two 
or more mucous membranes and skin involvement is 
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more variable. A severe variant of EM major is Stevens-
Johnson syndrome, which is characterized by extensive 
skin involvement (1).
A wide range of drugs can give rise to EM and it may be 
difficult to clinically distinguish drug-induced EM from 
disease due to other causes (3,4). Previous medication 
use has been identified in 59% of cases of EM (5) and 
there has been a striking increase in the number of cases 
caused by drugs. More than 100 different compounds 
have been implicated in dermatological diseases (3).
Alendronate sodium was approved by the Food and 
Drug Administration for the prevention and treatment 
of osteoporosis in postmenopausal women and for the 
treatment of Paget’s disease. Alendronate belongs to a 
class of synthetic compounds known as bisphosphona-
tes, which adhere strongly to hydroxyapatite crystals 
and inhibit bone resorption (6). The most common ad-
verse events associated with alendronate sodium use are 
nausea/vomiting, nonspecific gastrointestinal events, 
abdominal pain, dyspepsia, diarrhea, dysphagia, and a 
skin rash (7). 
This study reports an uncommon case of EM minor in a 
96-year-old woman associated with the use of alendro-
nate sodium. In addition, a Medline search comprising 
the period from 1998 to June 2016 was performed using 
the following keywords: erythema multiforme minor, 
erythema multiforme minor in oral and maxillofacial, 
and erythema multiforme minor by drugs.
Case Report
A 96-year-old woman was referred by her geriatrician to 
the Oral Medicine Clinic, School of Dentistry, Federal 
University of Minas Gerais (UFMG), for evaluation of 
lesions on the lower lip and right cheek, which made ea-
ting difficult. Her medical history revealed osteoporotic 
disease, dementia syndrome, severe postural instability, 
congenital deafness, hypovitaminosis, peripheral venous 
insufficiency, and recurrent urinary tract infection. The 
socioeconomic history was not contributory. Intraoral 
clinical examination demonstrated hypersalivation and 
macrocheilia of the lower lip, associated with an ill-defi-
ned ulcer with erythematous borders measuring 20 mm 
in greatest diameter and covered with serofibrinous exu-
dates. Other ulcers with the same features were observed 
in the right oral mucosa (Fig. 1 A,B). The patient was ta-
king the following medications: B complex, calcium car-
bonate, anticoagulant, sulfamethoxazole/trimethoprim, 
and alendronate sodium. Treatment with alendronate so-
dium had been initiated 2 weeks before the onset of oral 
signs and symptoms for the prevention of osteoporotic 
fractures. Based on the clinical and anamnesis findings, 
the initial clinical diagnosis was drug-induced EM minor. 
Alendronate sodium, B complex and calcium carbonate 
were discontinued and antibiotic therapy was terminated. 
Analgesics, local cleaning and clinical follow-up were 
Fig. 1:  A) Well-defined ulcer located on the lower lip measuring 20 
mm in greatest diameter. Note the accumulation of saliva due to sia-
lorrhea. B) Well-defined ulcer located on the oral mucosa measuring 
approximately 10 mm.
prescribed. The oral lesions had completely healed after 2 
weeks. In agreement with the geriatrician, treatment with 
alendronate sodium was restarted and the same signs and 
symptoms appeared again 14 days later. The final clinical 
diagnosis was EM minor induced by alendronate sodium. 
The other medications were reintroduced and no signs and 
symptoms were observed after 4 weeks. After 24 months 
of follow-up, the patient shows no signs of recurrence. 
The patient signed the correspondent informed consent 
for the publication of this clinical case report.
Discussion
Erythema multiforme is characterized by an acute onset 
and a wide spectrum of severity ranging from EM minor 
to EM major, traditionally known as Stevens-Johnson 
syndrome, and toxic epidermal necrolysis (Lyell’s disea-
se) (8). The minor form of the disease manifests as ul-
cerations that primarily affect the oral mucosa. The oral 
lesions appear as erythematous plaques that undergo 
epithelial necrosis and progress to shallow ulcerations 
and erosions with irregular edges (4). In EM minor, the 
affected mucous membrane is limited to only one anato-
mical site, generally the oral mucosa (9). In the present 
case, the lesions occurred in a 96-year-old woman and 
only involved the oral mucosa. No lesions were obser-
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ved at other anatomical sites and the diagnosis was the 
minor variant of EM. 
A PubMed-Medline search was performed to identify ca-
Author (year) Age/Gender Cause Therapy Outcome Recurrence 
de Ocariz et al.
(1998)
6-mo/F Herpetic whitlow Acyclovir 5 
mg/kg/day, 10 days 
Regression No 
Abraham et al.
(2000)
44/F Herpes simplex 
infection 
40 mg oral 
prednisone daily, 6 
weeks 
Regression No 
Frederiksen et al.
(2004)
5-mo/M Diphtheria and tetanus 
vaccines 
Medical follow-up Regression No 
Frederiksen et al.
(2004)
5/F Diphtheria and tetanus 
vaccines 
Zinc liniment and 
medical follow-up 
Regression No 
Desarkar & Nizamie 
(2006)
21/M Risperidone Oral prednisolone, 
2 weeks 
Regression No 
Studdiford et al.
(2006)
20/M Meningitis vaccine Oral antihistamine 
(diphenhydramine) 
and cold 
compresses, 4 
weeks 
Regression No 
Lin et al. (2006) 21/F Quetiapine Medical follow-up, 
3 weeks 
Regression No 
Rodríguez-Pérez & 
Delgado-Álvarez 
(2006)
24/M Not informed Prednisone Regression No 
Barbosa & Teixeira 
(2008)
60/F Phenytoin and cranial 
radiation therapy 
Not informed Regression No 
Kaur & Handa 
(2008)
2-mo/F Vaccination for dpt, 
hepatitis b and influenza 
Not informed Not 
informed
Not
informed
Osterne et al. (2009) 11/M Herpes simplex 
infection 
Acyclovir 1000 
mg/day, 10 days 
Regression No 
Babu et al. (2010) 30/M Herpes simplex 
infection 
Prednisone 60 
mg/day, 6 weeks 
Regression No 
Desai & English 
(2013)
20/F Ibuprofen Triamcinolone 
ointment 0.1%, 10 
days 
Regression No 
Alfar et al. (2015) 10/M Herpes simplex 
infection 
Acyclovir 10 
mg/kg/dose, 8 
hours, orally 
Acetaminophen 15 
mg/kg, IV fluids 
and hydrocortisone 
IV injection 10 
mg/kg, 5 days 
Regression No 
Clinic (2016) 49/M Sildenafil Cetirizine 10 mg, 
twice daily, 7 days 
and a cream 
containing
polidocanol and 
urea
Regression No 
Present case 96/F Induced by alendronate 
sodium
Local cleaning and 
clinical follow-up 
Regression No 
ses of EM minor published in the English literature. The 
articles retrieved were analyzed regarding age, gender, 
cause, therapy used, outcome, and recurrence (Table 1). 
Table 1: Data of erythema multiforme minor cases published in PubMed-Medline from 1998 to 2016. 
M: male; F: female; mo: months.
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As can be seen, almost every decade of life was affected. 
No gender predilection was observed and the etiology 
was variable. There was no established treatment pro-
tocol, but removal of the causative agent was consensus 
among all authors. We found no reports in the literature 
associating EM minor with alendronate sodium.
The management of EM minor and major remains con-
troversial. In the past, the use of systemic or topical 
corticosteroids was advocated, especially in the early 
stages of the disease. Although there is little good clini-
cal evidence from controlled trials that this treatment is 
beneficial, it is generally used at most centers. If a cau-
sative drug is identified or suspected, treatment should 
be discontinued immediately. If the patient is dehydrated 
because of the inability to eat due to oral pain, intrave-
nous rehydration may be necessary along with topical 
anesthetic agents to reduce discomfort (10-12). In the 
present case, regression of the lesions was observed 
after discontinuation of the drugs used by the patient. 
Although resuming treatment with alendronate sodium 
may have resulted in the recurrence of EM, its definiti-
ve discontinuation led to complete regression within 24 
months of follow-up.
Mucosal involvement in EM minor and major varies ac-
cording to severity. Patients with minimal involvement, 
such as painful erosions, can be treated with high-po-
tency topical corticosteroid gel, oral antiseptic washes, 
and oral anesthetic solutions. Unfortunately, in some pa-
tients, extensive mucosal involvement and debilitating 
pain prevent sufficient oral intake. These patients require 
systemic glucocorticoids (e.g., 40–60 mg/d prednisone, 
with the dose tapered over 2-4 weeks) to reduce severity 
and disease duration, although there are no controlled 
studies to support this recommendation (11,13).
Although EM is self-limiting, lasting 2 to 6 weeks, about 
20% of patients experience recurrent episodes, usually 
in the spring and autumn. If the disease is triggered by 
herpes simplex, continuous oral acyclovir or valacyclo-
vir therapy may prevent recurrences. Persistence of EM 
lesions is rare. In most cases, EM is not life-threatening, 
except for its most severe form (10-12). Scully & Bagan 
(1) and Stewart et al. (5) recommend any precipitants of 
EM to be removed or treated and the causative drug to 
be discontinued. There is no specific treatment for EM 
minor. Despite controversies, corticosteroids and anal-
gesics are the drugs most commonly used for the mana-
gement of patients with EM. 
The diagnosis of EM is mainly clinical. Some lesions 
occurring in the skin are highly characteristic of the di-
sease. Since there are no specific diagnostic tests for EM, 
the diagnosis is generally supported by a perilesional tis-
sue biopsy and exclusion of other causes. The histopa-
thological pattern of the perilesional mucosa in EM is 
characteristic but not pathognomonic. Patients typically 
experience prodromal symptoms such as fever, malaise, 
headache, cough and a sore throat that can occur one 
week before the onset of the disease (1). According to 
Ayangco & Rogers (4), the diffuse clinical appearance 
and oral ulcerations can be difficult to differentiate from 
other immunopathological disorders and the differential 
diagnosis must therefore include erosive lichen planus, 
pemphigus, pemphigoid, and linear IgA dermatosis (14). 
In the present case, the diagnosis was based on clinical 
presentation, association with drug use, and exclusion of 
other vesiculobullous diseases.
Although little is known about the molecular and cellu-
lar mechanisms that trigger EM, this disorder responds 
primarily to antigens that are induced by exposure to mi-
crobes or drugs (4). Microbial agents have been reported 
to trigger EM, particularly herpes simplex which is im-
plicated in up to 70% of recurrent cases. EM is known to 
be related to cytotoxic T lymphocytes and specific CD8+ 
cells that are activated in response to antigens of drugs. 
Activation of the Fas membrane receptor, which is pre-
sent in the cell membrane of keratinocytes, by its ligand 
FasL induces keratinocyte apoptosis through activation 
of specific enzymes called caspases (13,15).
The main drug classes associated with EM minor and 
major are: 1) anti-bacterial: sulfonamides (trimetho-
prim-sulfamethoxazole), aminopenicillins, cephalospo-
rins, quinolones, and tetracyclines; 2) anticonvulsants; 
3) analgesics; 4) nonsteroidal anti-inflammatory drugs, 
and 4) antifungals. Adverse reactions to alendronate so-
dium such as nausea, vomiting, abdominal pain, dyspep-
sia, and reflux esophagitis have been described in the 
literature (7,15). The clinical features of the present case 
support the diagnosis of EM minor caused by alendro-
nate sodium, in agreement with Biswas et al. (7) who 
reported the case of a patient that used the same drug and 
developed this skin disease.
The aging of the population in developed and develo-
ping countries has increased the use of alendronate so-
dium to prevent osteoporosis. Skin reactions triggered 
by drugs can be challenging to distinguish from other 
vesiculobullous lesions. Knowledge of clinical practitio-
ners about EM is important for the early diagnosis and 
raising awareness on the risks of indiscriminate drug use 
is necessary to reduce the occurrence of this disease.
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